Drug Discovery, Designing Chemistry and Pharmaceutical Analysis

“Biobetters” or “Biosuperiors” are enhanced versions of approved biological products. Whereas “Biosimilars” are near-perfect copies of the originators, biobetters diff erentiate themselves through displaying superiority over the reference biologics.These improvements in one or more attributes could be in the form of increased effi cacy and/or safety, reduced immunogenicity, changes in route of delivery, reduced dosing frequency/cost of treatment or improvements in manufacturing. Inspite of these potential advantages over the branded biologic or an approved biosimilar, biobetters also face various clinical development, regulatory and marketing hurdles which will be addressed. In summary, biobetters represent an opportunity to establish brand-to-brand competition within treatment indications and can be perceived as a potential path to provide meaningful improvements over the original biologic, sustain innovation and market diff erentiation in order to drive future value.